Honeywell HomMed Announces LifeStream Leaders Advantage Program To Help Providers Better Implement, Market Telehealth Programs

 

BROOKFIELD, Wis. – April 1, 2013 – Honeywell (NYSE: HON) HomMed, a global leader in telehealth and remote patient care, today announced its LifeStream Leaders Advantage Program, designed to support healthcare providers as they implement, market and grow their telehealth programs. 

With LifeStream Leaders Advantage, healthcare providers can tap into Honeywell HomMed’s network of marketing assets and clinical expertise – including educational opportunities, access to marketing funds and vertical marketing kits – to ensure they have the right tools in place to successfully communicate the benefits of their telehealth programs to patients and referral sources, such as physicians and hospitals. 

"Giving our customers the support they need to make their telehealth programs successful benefits everyone across the care continuum – from providers to physicians to patients,” said John Bojanowski, president-Honeywell HomMed. 


The LifeStream Leaders Advantage program has three membership levels: Gold, Silver and Bronze, and provides a wide range of benefits, including access to market development funds, on-site clinical consultation support throughout the calendar year, the ability to become a member of HomMed’s advisory board, and marketing planning support. At the Gold and Silver membership levels, participants can also accrue Market Development Funds that allow them to select from an array of additional marketing and clinical support activities, including clinical visits, goal setting, company-wide email campaigns and online optimization support. 

"The program was developed to support our customers as they communicate the benefits of a telehealth program to their customers,” said Wendy Tobin, Manager of Channel Marketing of Honeywell HomMed, and the Program’s designer.  “We created the tiers in the program to provide the level of assistance our customers need, based on the size and scope of their existing telehealth program, and offer our support as they expand their programs in the future.”

 

For more information about Honeywell HomMed’s LifeStream Leaders Advantage Program, please visit: www.hommed.com/leaders-advantage.

 

About Honeywell:

Honeywell International (www.honeywell.com) is a Fortune 100 diversified technology and manufacturing leader, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, N.J., Honeywell's shares are traded on the New York, London, and Chicago Stock Exchanges. For more news and information on Honeywell, please visit www.honeywellnow.com.

 

About Honeywell HomMed:

Honeywell HomMed is part of the Honeywell Automation and Control Solutions business group, a global leader in providing product and service solutions that improve efficiency and profitability, support regulatory compliance, and maintain safe, comfortable environments in homes, buildings and industry. For more information about Honeywell HomMed, please visit www.hommed.com.

 

This release contains certain statements that may be deemed “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, that address activities, events or developments that we or our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this release are also subject to a number of material risks and uncertainties, including but not limited to economic, competitive, governmental, and technological factors affecting our operations, markets, products, services and prices. Such forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ from those envisaged by such forward-looking statements.

 

 

 

 

 

 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.